Advancing insights into Lp(a) as a causal factor in CVD - PACE-CME

Advancing insights into Lpa as a causal factor in CVD

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

FCS and SHTG: Are We Meeting the Need?
FCS and SHTG: Are We Meeting the Need?
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
- Ira J. Goldberg, MD
- Kausik Ray, MBChB, MD, MPhil
- Christie Ballantyne
0.25 credits
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
AHA 2024
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
MinuteCE®
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
0.75 program credits
- Julia Brandts, MD
0.75 program credits